Riesgos, fenotipos y comparación de tratamiento de EPOC en atención primaria según guías GOLD y GesEPOC

Global Initiative for Chronic Obstructive Pulmonary Lung Disease (GOLD) 2019. Global strategy for the diagnosis, management and prevention of COPD. 2019 Report. Disponible en: www.goldcopd.org Soriano, 2010, Recent trends in COPD prevalence in Spain: A repeated cross-sectional survey 1997-2007, Eur Respir J., 36, 758, 10.1183/09031936.00138409 Cho, 2019, Which physicians are taking care of people with COPD?, Chest., 155, 771, 10.1016/j.chest.2018.12.018 2017, Guía de práctica clínica para el diagnóstico y tratamiento de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) – guía española de la EPOC (GesEPOC). Versión 2017, Arch Bronconeumol., 53, 532 García García, 2017, Enfermedad pulmonar obstructiva crónica: los pacientes en la vida real. Estudio LEONPOC, Aten Primaria., 49, 603, 10.1016/j.aprim.2017.01.002 Álvarez, 2014, Do we classify by feeling mixed COPD-asthma phenotype patients with GesEPOC?, European Respiratory Society International Congress. Munich, Germany, 6 Latour, 1997, Métodos de investigación en cardiología clínica (IV). Las mediciones clínicas en cardiología: validez y errores de medición, Rev Esp Cardiol., 50, 117, 10.1016/S0300-8932(97)73190-7 Tsiligianni, 2019, COPD patients’ characteristics, usual care, and adherence to guidelines: The Greek UNLOCK study, Int J Chron Obstruct Pulmon Dis., 14, 547, 10.2147/COPD.S185362 Dal Negro, 2015, Prevalence of different comorbidities in COPD patients by gender and GOLD stage, Multidiscip Respir Med., 10, 24, 10.1186/s40248-015-0023-2 Izquierdo, 2018, Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD groups and GesEPOC clinical phenotypes, Arch Bronconeumol., 54, 559, 10.1016/j.arbres.2018.03.021 Miravitlles, 2017, The variability of respiratory symptoms and associated factors in COPD, Respir Med., 129, 165, 10.1016/j.rmed.2017.06.017 Sobradillo Peña, 1997, Proyecto IBERPOC: un estudio epidemiológico de la EPOC en España, Arch Bronconeumol., 33, 293, 10.1016/S0300-2896(15)30599-8 Terzikhan, 2016, Prevalence and incidence of COPD in smokers and non-smokers: The Rotterdam study, Eur J Epidemiol., 31, 785, 10.1007/s10654-016-0132-z Raherison, 2018, Comorbidities and COPD severity in a clinic-based cohort, BMC Pulm Med., 18, 117, 10.1186/s12890-018-0684-7 Chetty, 2017, Chronic obstructive pulmonary disease and comorbidities: A large cross-sectional study in primary care, Br J Gen Pract., 67, 321, 10.3399/bjgp17X690605 Calle, 2018, Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL, Arch Bronconeumol., 54, 270, 10.1016/j.arbres.2017.11.015 Barrecheguren, 2016, Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study, Respir Med., 111, 47, 10.1016/j.rmed.2015.12.004 Miravitlles, 2015, Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease, Int J Tuberc Lung Dis., 19, 992, 10.5588/ijtld.15.0021 Calle Rubio, 2017, Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD guidelines: The FENEPOC study, Int J Chron Obstruct Pulmon Dis., 12, 2373, 10.2147/COPD.S137872 De Abajo Larriba, 2017, Estimación de la prevalencia de los fenotipos en pacientes con enfermedad pulmonar obstructiva crónica. Estudio ADEPOCLE, Nutr Hosp., 34, 180, 10.20960/nh.995 Singh, 2014, Eosinophilic inflammation in COPD: Prevalence and clinical characteristics, Eur Respir J., 44, 1697, 10.1183/09031936.00162414 Watz, 2009, Physical activity in patients with COPD, Eur Resp J., 33, 262, 10.1183/09031936.00024608 Bloom, 2020, Inhaled corticosteroid treatment regimens and health outcomes in a UK COPD population study, Int J Chron Obstruct Pulmon Dis., 15, 701, 10.2147/COPD.S241568 Sulku, 2019, A cross-sectional study assessing appropriateness of inhaled corticosteroid treatment in primary and secondary care patients with COPD in Sweden, Int J Chron Obstruct Pulmon Dis., 14, 2451, 10.2147/COPD.S218747 Casas, 2018, Respiratory medication used in COPD patients from seven Latin American countries: The LASSYC study, Int J Chron Obstruct Pulmon Dis., 13, 1545, 10.2147/COPD.S154097 Bourbeau, 2008, Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study, Can Respir J., 15, 13, 10.1155/2008/173904 Izquierdo, 2018, Characteristics of COPD patients managed in respiratory medicine departments in Spain according to GOLD groups and GesEPOC clinical phenotypes, Arch Bronconeumol., 54, 559, 10.1016/j.arbres.2018.03.021